JPH07509127A - 偽狂犬病ウイルス変異株を含むアウジェスキー病及び他の動物疾病に対するワクチン - Google Patents
偽狂犬病ウイルス変異株を含むアウジェスキー病及び他の動物疾病に対するワクチンInfo
- Publication number
- JPH07509127A JPH07509127A JP6503188A JP50318894A JPH07509127A JP H07509127 A JPH07509127 A JP H07509127A JP 6503188 A JP6503188 A JP 6503188A JP 50318894 A JP50318894 A JP 50318894A JP H07509127 A JPH07509127 A JP H07509127A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- gene
- disease
- vaccine
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 title claims description 59
- 229960005486 vaccine Drugs 0.000 title claims description 54
- 201000010099 disease Diseases 0.000 title claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 31
- 208000031295 Animal disease Diseases 0.000 title claims description 13
- 101000686824 Enterobacteria phage N4 Virion DNA-directed RNA polymerase Proteins 0.000 claims description 136
- 101000644628 Escherichia phage Mu Tail fiber assembly protein U Proteins 0.000 claims description 136
- 241000700605 Viruses Species 0.000 claims description 116
- 208000015181 infectious disease Diseases 0.000 claims description 73
- 230000002458 infectious effect Effects 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 26
- 238000012217 deletion Methods 0.000 claims description 19
- 230000037430 deletion Effects 0.000 claims description 19
- 238000003780 insertion Methods 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 7
- 241001529453 unidentified herpesvirus Species 0.000 claims description 7
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 229940126580 vector vaccine Drugs 0.000 claims description 3
- 108010059485 brain synaptic membrane glycoprotein gp 50 Proteins 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 208000009305 pseudorabies Diseases 0.000 claims description 2
- 101150030521 gI gene Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 65
- 241001465754 Metazoa Species 0.000 description 57
- 101001095863 Enterobacteria phage T4 RNA ligase 1 Proteins 0.000 description 41
- 239000013612 plasmid Substances 0.000 description 41
- 239000012634 fragment Substances 0.000 description 39
- 241000282887 Suidae Species 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 239000013598 vector Substances 0.000 description 18
- 206010037660 Pyrexia Diseases 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 14
- 231100000419 toxicity Toxicity 0.000 description 12
- 230000001988 toxicity Effects 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 210000004556 brain Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000002238 attenuated effect Effects 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 241000282898 Sus scrofa Species 0.000 description 9
- 230000005540 biological transmission Effects 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 230000006798 recombination Effects 0.000 description 9
- 238000005215 recombination Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 101150029662 E1 gene Proteins 0.000 description 8
- 206010053759 Growth retardation Diseases 0.000 description 8
- 206010060860 Neurological symptom Diseases 0.000 description 8
- 101150118312 gp63 gene Proteins 0.000 description 8
- 231100000001 growth retardation Toxicity 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000001018 virulence Effects 0.000 description 8
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- 206010033799 Paralysis Diseases 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 231100000219 mutagenic Toxicity 0.000 description 6
- 230000003505 mutagenic effect Effects 0.000 description 6
- 241000710777 Classical swine fever virus Species 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 206010003591 Ataxia Diseases 0.000 description 4
- 241000701083 Bovine alphaherpesvirus 1 Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine kinase Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 210000000578 peripheral nerve Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 241000700618 Vaccinia virus Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 101800001466 Envelope glycoprotein E1 Proteins 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000711493 Porcine respiratory coronavirus Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 230000003363 transsynaptic effect Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700664 Capripoxvirus Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000666730 Homo sapiens T-complex protein 1 subunit alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- ZQISRDCJNBUVMM-UHFFFAOYSA-N L-Histidinol Natural products OCC(N)CC1=CN=CN1 ZQISRDCJNBUVMM-UHFFFAOYSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 101100185263 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mde-1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 101710123496 Spindolin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100038410 T-complex protein 1 subunit alpha Human genes 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 238000009412 basement excavation Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005101 cell tropism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000011999 immunoperoxidase monolayer assay Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007919 viral pathogenicity Effects 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16761—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92202096.1 | 1992-07-09 | ||
| EP92202096 | 1992-07-09 | ||
| PCT/NL1993/000146 WO1994001573A1 (en) | 1992-07-09 | 1993-07-08 | Vaccines against aujeszky's disease and other animal diseases containing pseudorabies virus mutants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07509127A true JPH07509127A (ja) | 1995-10-12 |
Family
ID=8210764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6503188A Pending JPH07509127A (ja) | 1992-07-09 | 1993-07-08 | 偽狂犬病ウイルス変異株を含むアウジェスキー病及び他の動物疾病に対するワクチン |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5674500A (enExample) |
| EP (1) | EP0654086B1 (enExample) |
| JP (1) | JPH07509127A (enExample) |
| KR (1) | KR100341994B1 (enExample) |
| CN (1) | CN1124159C (enExample) |
| AT (1) | ATE189000T1 (enExample) |
| AU (1) | AU684252B2 (enExample) |
| CA (1) | CA2139507C (enExample) |
| DE (1) | DE69327656T2 (enExample) |
| DK (1) | DK0654086T3 (enExample) |
| ES (1) | ES2143507T3 (enExample) |
| HU (1) | HU220099B (enExample) |
| NZ (1) | NZ254267A (enExample) |
| PL (1) | PL174219B1 (enExample) |
| RU (1) | RU2158308C2 (enExample) |
| TW (1) | TW289731B (enExample) |
| WO (1) | WO1994001573A1 (enExample) |
| ZA (1) | ZA934882B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2103460C (en) * | 1991-06-06 | 2000-09-26 | Gert Wensvoort | Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
| US6007825A (en) * | 1991-12-23 | 1999-12-28 | American Cyanamid Company | Serpulina hyodysenteriae vaccine comprising a tly gene mutant |
| US7223411B1 (en) | 1992-07-31 | 2007-05-29 | Dana-Farber Cancer Institute | Herpesvirus replication defective mutants |
| US6380376B1 (en) * | 1992-10-30 | 2002-04-30 | Iowa State University Research Foundation | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| US6773908B1 (en) * | 1992-10-30 | 2004-08-10 | Iowa State University Research Foundation, Inc. | Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV) |
| US6592873B1 (en) * | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
| WO1994021807A2 (en) * | 1993-03-19 | 1994-09-29 | Cantab Pharmaceuticals Research Limited | Defective mutant non-retroviral virus (e.g. hsv) as vaccine |
| EP0659885A1 (en) * | 1993-12-21 | 1995-06-28 | Akzo Nobel N.V. | Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity |
| EP0693551A1 (en) | 1994-07-18 | 1996-01-24 | Akzo Nobel N.V. | gD-negative bovine herpesvirus mutant, capable of direct cell-to-cell transmission |
| WO2000053787A1 (en) * | 1999-03-08 | 2000-09-14 | Id-Lelystad, Instituut Voor Dierhouderij En Dierg Ezondheid B.V. | Prrsv vaccines |
| EP0839912A1 (en) * | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| US20040224327A1 (en) * | 1996-10-30 | 2004-11-11 | Meulenberg Johanna Jacoba Maria | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
| US6399354B1 (en) | 1998-07-31 | 2002-06-04 | President And Fellows Of Harvard College | Replication-competent virus expressing a detectable fusion protein |
| EP2251419B1 (en) * | 1999-04-22 | 2012-05-30 | United States Department of Agriculture | Porcine reproductive and respiratory syndrome vaccine, based on isolate JA-142 |
| US20050014264A1 (en) * | 2002-12-11 | 2005-01-20 | University Of Massachusetts | Method of introducing siRNA into adipocytes |
| JP2008503727A (ja) * | 2004-06-18 | 2008-02-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ウイルス感染した生物およびワクチン接種した生物の同定 |
| US7632636B2 (en) * | 2004-09-21 | 2009-12-15 | Boehringer Ingelheim Vetmedica, Inc. | Porcine reproductive and respiratory syndrome isolates and methods of use |
| EP2369001B1 (en) | 2005-06-24 | 2016-08-31 | Regents of the University of Minnesota | PRRS viruses, infectious clones, mutants thereof, and methods of use |
| CN101081298A (zh) * | 2007-06-26 | 2007-12-05 | 陈少莺 | 一种猪伪狂犬病新型亚单位疫苗制备方法 |
| WO2010025109A1 (en) * | 2008-08-25 | 2010-03-04 | Boehringer Ingelheim Vetmedia, Inc. | Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (hp prrs) |
| CN101457215B (zh) * | 2008-12-01 | 2010-11-17 | 华中农业大学 | 重组猪伪狂犬病毒-猪繁殖与呼吸综合征病毒-猪圆环病毒基因工程毒株及应用 |
| AR078253A1 (es) * | 2009-09-02 | 2011-10-26 | Boehringer Ingelheim Vetmed | Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad |
| RU2439150C1 (ru) * | 2010-11-16 | 2012-01-10 | Государственное научное учреждение Всероссийский научно-исследовательский институт ветеринарной вирусологии и микробиологии | Штамм "ас-21/07" вируса ауески для изготовления вакцинных и диагностических препаратов |
| CN103370077B (zh) | 2011-02-17 | 2016-10-26 | 贝林格尔.英格海姆维特梅迪卡有限公司 | 猪繁殖与呼吸综合征病毒的商业化规模生产方法 |
| SG192820A1 (en) | 2011-02-17 | 2013-09-30 | Boehringer Ingelheim Vetmed | Novel european prrsv strain |
| US9187731B2 (en) | 2011-07-29 | 2015-11-17 | Boehringer Ingelheim Vetmedica Gmbh | PRRS virus inducing type I interferon in susceptible cells |
| EP2737058A1 (en) | 2011-07-29 | 2014-06-04 | Boehringer Ingelheim Vetmedica GmbH | INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
| CN105073130A (zh) | 2013-03-15 | 2015-11-18 | 勃林格殷格翰动物保健公司 | 猪生殖与呼吸综合征病毒、组合物、疫苗及使用方法 |
| CN104250640A (zh) * | 2014-08-22 | 2014-12-31 | 普莱柯生物工程股份有限公司 | 猪伪狂犬病病毒基因缺失株、疫苗组合物及其制备方法和应用 |
| CN111560355A (zh) * | 2015-03-20 | 2020-08-21 | 普莱柯生物工程股份有限公司 | 一种猪伪狂犬病病毒致弱方法、及其致弱的病毒株、疫苗组合物和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859587A (en) * | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
| EP0231209B1 (en) * | 1985-07-29 | 1991-02-06 | The Upjohn Company | Virus vaccine |
| US5352575A (en) * | 1985-10-04 | 1994-10-04 | The Upjohn Company | Pseudorabies virus protein |
| US4999296A (en) * | 1986-04-29 | 1991-03-12 | Novagene, Inc. | Thymidine kinase negative insertion mutants of pseudorabies virus and methods for the production of same |
| NL8902087A (nl) * | 1989-08-17 | 1991-03-18 | Stichting Tech Wetenschapp | Niet-natuurlijk voorkomend pseudorabiesvirus en vaccins die dit bevatten. |
| ATE194657T1 (de) * | 1990-09-25 | 2000-07-15 | Cantab Pharma Res | Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff |
| ATE288483T1 (de) * | 1992-07-30 | 2005-02-15 | Akzo Nobel Nv | Nicht-verbreitendes lebendes herpesvirusvakzin |
-
1993
- 1993-07-02 TW TW82105279A patent/TW289731B/zh active
- 1993-07-07 ZA ZA934882A patent/ZA934882B/xx unknown
- 1993-07-08 CA CA 2139507 patent/CA2139507C/en not_active Expired - Fee Related
- 1993-07-08 RU RU95105518A patent/RU2158308C2/ru not_active IP Right Cessation
- 1993-07-08 HU HU9500039A patent/HU220099B/hu not_active IP Right Cessation
- 1993-07-08 JP JP6503188A patent/JPH07509127A/ja active Pending
- 1993-07-08 ES ES93916297T patent/ES2143507T3/es not_active Expired - Lifetime
- 1993-07-08 WO PCT/NL1993/000146 patent/WO1994001573A1/en not_active Ceased
- 1993-07-08 DK DK93916297T patent/DK0654086T3/da active
- 1993-07-08 US US08/373,325 patent/US5674500A/en not_active Expired - Fee Related
- 1993-07-08 KR KR1019950700064A patent/KR100341994B1/ko not_active Expired - Fee Related
- 1993-07-08 PL PL93307049A patent/PL174219B1/pl not_active IP Right Cessation
- 1993-07-08 AU AU45898/93A patent/AU684252B2/en not_active Ceased
- 1993-07-08 AT AT93916297T patent/ATE189000T1/de not_active IP Right Cessation
- 1993-07-08 DE DE69327656T patent/DE69327656T2/de not_active Expired - Fee Related
- 1993-07-08 EP EP19930916297 patent/EP0654086B1/en not_active Expired - Lifetime
- 1993-07-08 NZ NZ254267A patent/NZ254267A/en unknown
- 1993-07-09 CN CN93108005A patent/CN1124159C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ZA934882B (en) | 1994-02-03 |
| DE69327656D1 (de) | 2000-02-24 |
| HU9500039D0 (en) | 1995-03-28 |
| CN1124159C (zh) | 2003-10-15 |
| WO1994001573A1 (en) | 1994-01-20 |
| TW289731B (enExample) | 1996-11-01 |
| EP0654086A1 (en) | 1995-05-24 |
| PL307049A1 (en) | 1995-05-02 |
| CA2139507C (en) | 2005-04-19 |
| PL174219B1 (pl) | 1998-06-30 |
| EP0654086B1 (en) | 2000-01-19 |
| DK0654086T3 (da) | 2000-06-13 |
| AU4589893A (en) | 1994-01-31 |
| KR100341994B1 (ko) | 2002-11-30 |
| AU684252B2 (en) | 1997-12-11 |
| CN1086143A (zh) | 1994-05-04 |
| RU95105518A (ru) | 1997-03-27 |
| ATE189000T1 (de) | 2000-02-15 |
| DE69327656T2 (de) | 2000-08-03 |
| CA2139507A1 (en) | 1994-01-20 |
| US5674500A (en) | 1997-10-07 |
| HUT70986A (en) | 1995-11-28 |
| RU2158308C2 (ru) | 2000-10-27 |
| ES2143507T3 (es) | 2000-05-16 |
| NZ254267A (en) | 1996-08-27 |
| HU220099B (hu) | 2001-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07509127A (ja) | 偽狂犬病ウイルス変異株を含むアウジェスキー病及び他の動物疾病に対するワクチン | |
| Card et al. | Pseudorabies virus envelope glycoprotein gI influences both neurotropism and virulence during infection of the rat visual system | |
| KR102070217B1 (ko) | 다가 재조합 조류 헤르페스 바이러스 및 조류 종을 면역화하기 위한 백신 | |
| EP0390799B1 (en) | Respiratory syncytial virus: vaccines | |
| KR100372934B1 (ko) | 형질 상보성 세포주에 의해 생성된 바이러스 결손 백신 | |
| RU2139729C1 (ru) | Вакцинная композиция, способ стимулирования иммунной системы | |
| JPH08333279A (ja) | ウイルスに感染した動物とワクチン接種した動物を区別する方法 | |
| JPH04505248A (ja) | ヘルペスウイルス組換えポックスウイルスワクチン | |
| US11896658B2 (en) | RSV vaccines and methods of production and use thereof | |
| US20230372474A1 (en) | Recombinant hvt and uses thereof | |
| US5626850A (en) | Non-shedding live herpesvirus vaccine | |
| Chanock et al. | Live viral vaccines for respiratory and enteric tract diseases | |
| JPH08502043A (ja) | ヘルペスウイルスワクチン | |
| US5149532A (en) | Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms | |
| Peeters et al. | Non-transmissible pseudorabies virus gp50 mutants: a new generation of safe live vaccines | |
| Meignier | Vaccination against herpes simplex virus infections | |
| Yang et al. | Safety and immunogenicity of recombinant rabies virus (ERAGS) in mice and raccoon dogs | |
| Kit et al. | Circumvention of maternal antibody interference by immunization of newborn pigs with glycoprotein gIII‐deleted marker vaccine | |
| Liu et al. | Current approaches to vaccine preparation | |
| JP2002512504A (ja) | 機能が不全な７１遺伝子領域を含む組換えウマヘルペスウィルス１型（ｅｈｖ−１）、および、そのワクチンとしての使用 | |
| CZ127394A3 (en) | Replication-capable recombinant virus, process of obtaining thereof and vaccine composition | |
| CN116656630A (zh) | 重组鸭瘟病毒疫苗及其构建方法和应用 | |
| WO1998004710A9 (en) | Live recombinant bhv/brsv vaccine | |
| WO1998004710A2 (en) | Live recombinant bhv/brsv vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20031216 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040219 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20040715 |